Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Oncimmune Limited
Breakthrough Status, Big Investments For Liquid Biopsies
The growth potential of liquid biopsy diagnostics is drawing increasing attention, with several recent breakthrough device designations from the US FDA, big funding rounds, and major acquisitions all in play.
Biodesix Buys US Laboratory Assets From Oncimmune
Biodesix is expanding its portfolio of lung cancer diagnostic tests and acquiring the US assets of UK company Oncimmune.
Tech Transfer Roundup: J&J Houses JPOD Incubator At University Of Pennsylvania
Pascal and Oblato separately license therapeutic candidates for glioblastoma multiforme, while Cabaletta emerges from UPenn with novel program for CAAR-T therapies in B-cell mediated autoimmune disease.
Device Debut: Oncimmune Pushes Liver Cancer Test In The US
Oncimmune has expanded its offering in the US with the launch of a blood-based liver cancer test, the second product to emerge from its EarlyCDT platform.
In Vitro Diagnostics
- Chemistry, Immunoassay
- Molecular Diagnostics & Genetic Testing
- Large Molecule
Drug Discovery Tools
- Other Names / Subsidiaries
- Protagen AG
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.